SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
NCT05286931
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neisseria Gonorrhoeae Infection
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Washington
- Last updated on ClinicalTrials.gov
- March 18, 2022
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Public Health -- Seattle & King County Sexual Health Clinic · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.